Anteo Diagnostics Key People

Chairman

John Hurrell, B.Sc, M.Sc (Qual), PhD, Fullbright Fellow

  • Independant Non-Executive Director (Feb 2013 – Nov 2016)
  • Independant Chairman (Nov 2016 – Sep 2017)
  • Interim Executive Chairman (Sep 2017 – Dec 2017)
  • Chairman (Jan 2018 – )

Dr Hurrell has more than 30 years experience in the global biotechnology and life science industries. He has a strong track record of success in starting, building, growing and improving the profitability, performance and value of life science and healthcare companies. Currently, Dr Hurrell is a Consultant to PTS Diagnostics Inc. and serves as both President, Asia Pacific Region and Chairman, PTS Diagnostics India Pvt. Ltd. Previous roles held include Senior Executive Vice President (International Business Division) at Seegene, Inc., President and General Manager at Focus Diagnostics, VP of Business Development at Quest Diagnostics as well as senior positions at Genzyme, Boehringer Mannheim, Merck Serono, and a number of other companies.

Non-Executive Director

Rolf Sickman, M.L.

  • Nomination and Remuneration Committee Member
  • Audit and Risk Committee Member
  • Non-Executive Director (Jan 2016 – )

Mr Sickman is currently Chairman of the Board at DIAsource Immunoassays SA and Non-Executive Board Member at Anteo. Prior to joining DIAsource, Rolf was the CEO of a real estate company established in the Netherlands overlooking a portfolio valued in excess of €400,000,000. Rolf’s career took a new turn in 2011 when he became a senior partner at a private multi family office along with one other senior member of his previous team. Today, he used his domain expertise in private equity, real estate, long term asset development and investment processes to build up an independent boutique investment office. They are successfully specialised in non-correlated alternative investment strategies.

Non-Executive Director 

Geoff Cumming, B.App.Sc, B.Sc.(Hons.), MBA, PhD, MAICD

  • Nomination and Remuneration Committee Member
  • Audit and Risk Committee Member
  • Managing Director and CEO (Jan 2009 – Jun 2016)
  • Non-Executive Director (Jun 2016 – )

Dr Cumming has over 20 years experience in the healthcare and biotechnology market. Geoff’s roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems – Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roche’s global organisation. Geoff was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. Dr Cumming is a Non-Executive Director of Medical Australia Limited (ASX: MLA) and Chairman of Sienna Cancer Diagnostics Limited (ASX:SDX).

Non-Executive Director

Matt Sanderson

  • Non-Executive Director (Oct 2017 – )

Mr Sanderson joined the Anteo board as a Non-Executive Director in October 2017. He has been a director of private investment companies investing in public and private companies for the last 10 years. At Anteo, Matt’s objective is to provide focus on strategy and profitable execution and commercial growth of the technology. He is also strongly focused on providing shareholders with a clear and concise communication platform.

 

Company Secretary

Julien McInally, B.Bus, CPA, MBA

  • Company Secretary (Aug 2017– )

Mr McInally has been a Director/CFO/Company Secretary and has over 16 years experience with publicly listed companies on the TSX, AIM, and ASX stock exchanges in the resources and agriculture related industries. He has expertise in capital raisings, mergers and acquisitions, project and asset evaluation, strategy, commercial agreements, statutory and management reporting and compliance and governance obligations of publicly listed companies.